Sponsor: Sen. Blackburn, Marsha (R-TN)3 cosponsorsIntroduced Sep 28, 2026
✆
In plain English
S. 5571, sponsored by Sen. Marsha Blackburn (R-TN), changes the rules for when biosimilar drugs become eligible for Medicare price negotiations. The bill amends the Social Security Act's Medicare provisions to alter the timing or conditions under which these lower-cost biological product alternatives can be negotiated for prices under the federal health program.
One email when they vote against their own party. Nothing else.
Nonpartisan · Unsubscribe in one click · We never sell your address
Track this bill
Get an alert when it moves to the next stage or gets a vote.
Share
Embed this tracker on your site
Paste this HTML into your blog post or website to show a live tracker for this bill.
The embedded card updates automatically as the bill progresses. Preview →
See something wrong on this page? Tell us what looks incorrect and what it should be — we’ll investigate and correct it.
Report incorrect information
Every figure on this site is supposed to trace back to an official source. If something
here is wrong, telling me is the fastest way it gets fixed — and corrections are
published.